WO2000015767A3 - Antigen-presenting cells and their use in therapy - Google Patents
Antigen-presenting cells and their use in therapy Download PDFInfo
- Publication number
- WO2000015767A3 WO2000015767A3 PCT/NL1999/000575 NL9900575W WO0015767A3 WO 2000015767 A3 WO2000015767 A3 WO 2000015767A3 NL 9900575 W NL9900575 W NL 9900575W WO 0015767 A3 WO0015767 A3 WO 0015767A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- presenting cells
- measurement
- tolerogenic
- antigen
- antigen presenting
- Prior art date
Links
- 210000000612 antigen-presenting cell Anatomy 0.000 title abstract 5
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000005259 measurement Methods 0.000 abstract 5
- 230000003614 tolerogenic effect Effects 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000006044 T cell activation Effects 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000016396 cytokine production Effects 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0648—Splenocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4612—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464476—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/464817—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU57643/99A AU5764399A (en) | 1998-09-15 | 1999-09-15 | Antigen-presenting cells and their use in therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98203083 | 1998-09-15 | ||
EP98203083.5 | 1998-09-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000015767A2 WO2000015767A2 (en) | 2000-03-23 |
WO2000015767A3 true WO2000015767A3 (en) | 2000-07-20 |
Family
ID=8234113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL1999/000575 WO2000015767A2 (en) | 1998-09-15 | 1999-09-15 | Antigen-presenting cells and their use in therapy |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5764399A (en) |
WO (1) | WO2000015767A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9528088B2 (en) | 2002-06-28 | 2016-12-27 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190359939A1 (en) * | 2015-08-23 | 2019-11-28 | Diamyd Medical Ab | New use |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994005323A1 (en) * | 1992-09-04 | 1994-03-17 | The Johns Hopkins University School Of Medicine | Method for induction of antigen-specific immune tolerance |
US5623056A (en) * | 1989-03-15 | 1997-04-22 | Tkb Associates Limited Partnership | CDS derivatives and methods of use for cellular modulation and enhancement of cellular engraftment |
EP0856314A1 (en) * | 1995-04-07 | 1998-08-05 | Chugai Seiyaku Kabushiki Kaisha | Immunosuppressant |
-
1999
- 1999-09-15 WO PCT/NL1999/000575 patent/WO2000015767A2/en active Application Filing
- 1999-09-15 AU AU57643/99A patent/AU5764399A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5623056A (en) * | 1989-03-15 | 1997-04-22 | Tkb Associates Limited Partnership | CDS derivatives and methods of use for cellular modulation and enhancement of cellular engraftment |
WO1994005323A1 (en) * | 1992-09-04 | 1994-03-17 | The Johns Hopkins University School Of Medicine | Method for induction of antigen-specific immune tolerance |
EP0856314A1 (en) * | 1995-04-07 | 1998-08-05 | Chugai Seiyaku Kabushiki Kaisha | Immunosuppressant |
Non-Patent Citations (4)
Title |
---|
MANNIE M D ET AL: "Anergy-associated T cell antigen presentation. A mechanism of infectious tolerance in experimental autoimmune encephalomyelitis.", JOURNAL OF IMMUNOLOGY, (1996 AUG 1) 157 (3) 1062-70., XP002133088 * |
TAAMS LEONIE S ET AL: "Anergic T cells actively suppress T cell responses via the antigen-presenting cell.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 28, no. 9, September 1998 (1998-09-01), pages 2902 - 2912, XP000877447, ISSN: 0014-2980 * |
VAN RENSEN ANNEMIEK J M L ET AL: "Specific T cell activation and induction of T cell unresponsiveness by MHC II/peptide liposomes.", JOURNAL OF LIPOSOME RESEARCH, vol. 8, no. 1, February 1998 (1998-02-01), pages 117, XP000877083, ISSN: 0898-2104 * |
WAUBEN M H M ET AL: "Anergic T cells down-regulate the T cell activating capacity of APC.", 2ND INTERNATIONAL CONGRESS ON AUTOIMMUNITY; MARCH 7-11, 1999, no. SUPPL., 1999, Journal of Autoimmunity, pages 50, XP000877448, ISSN: 0896-8411 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9528088B2 (en) | 2002-06-28 | 2016-12-27 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
Also Published As
Publication number | Publication date |
---|---|
WO2000015767A2 (en) | 2000-03-23 |
AU5764399A (en) | 2000-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2369595A (en) | In vitro growth of functional islets of langerhans and in vivo uses thereof | |
ZA975851B (en) | Hepatocyte grown factor receptor agonists and uses thereof | |
EP2172476A3 (en) | Compositions and methods for WT1 specific immunotherapy | |
AU5756298A (en) | Attenuated salmonella strain used as a vehicle for oral immunization | |
DK1634949T3 (en) | Method of generating activated T cells and antigen-incubated antigen-presenting cells | |
TR200200137T2 (en) | Nucleotide analog compositions. | |
IL198285A0 (en) | Process for the measurement of the potency of glatiramer acetate | |
MY139226A (en) | Compositions and methods for wt1 specific immunotherapy | |
IL111734A0 (en) | Compositions for the preparation of in vivo therapeutic products | |
NZ502358A (en) | Hydrogel composition comprising a biologically active substance combined with a macromer | |
IL161832A0 (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
ATE361977T1 (en) | IN VITRO METHOD FOR INDUCING REGULATED PANCREATIC HORMONE PRODUCTION IN NON-PANCREATIC ISLAND TISSUES, ASSOCIATED PHARMACEUTICAL COMPOSITIONS | |
ATE399022T1 (en) | COMPOSITION AND METHOD FOR ENHANCING THE IMMUNE RESPONSE OF ANTIGEN-PRESENTING CELLS | |
CA2492938A1 (en) | Cancer vaccines containing epitopes of oncofetal antigen | |
WO2000015767A3 (en) | Antigen-presenting cells and their use in therapy | |
NO983177L (en) | Use of the 1-enantiomer of centroman for the preparation of a pharmaceutical composition for the treatment or prophylaxis of breast cancer | |
AU2164197A (en) | Recombinant adenoviral vectors for human tumour gene therapy | |
EP0202642A3 (en) | Process for the in vitro immunization of human splenocytes against tumor associated antigens | |
WO2002098361A3 (en) | T cell induced tissue repair and regeneration | |
DE60327710D1 (en) | MODIFIED CYTOKINS FOR CANCER THERAPY | |
EP0684831A4 (en) | Allogeneic vaccine and method to synthesize same. | |
AU2002352011A1 (en) | Immunogenic alk (anaplastic lymphoma kinase) peptides | |
GEP20063973B (en) | Streptogramin derivatives, production thereof and compositions containing them | |
AU7357894A (en) | Native-state method and system for determining viability and proliferative capacity of tissues (in vitro) | |
ES2058478T3 (en) | PROCEDURE FOR THE PREPARATION OF TRANS-BETA-LACTAMAS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |